Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines

Molecular Cancer Research

Volumn 8, Issue 10, 2010, Pages 1344-1357

  Bunt, Jens ^a   De Haas, Talitha G ^a   Hasselt, Nancy E ^a   Zwijnenburg, Danny A ^a   Koster, Jan ^a   Versteeg, Rogier ^a   Kool, Marcel ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; BETA GALACTOSIDASE; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 25C; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN G2; CYCLINE; INTERLEUKIN 6; MESSENGER RNA; MYC PROTEIN; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 7; TRANSCRIPTION FACTOR OTX2; UNCLASSIFIED DRUG;

ARTICLE; CELL AGING; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

CELL AGING; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDULLOBLASTOMA; OTX TRANSCRIPTION FACTORS;

EID: 78649660332     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0546     Document Type: Article

References (52)

1. Michiels EM, Oussoren E, Van Groenigen M, et al. Genes differentially expressed in medulloblastoma and fetal brain. Physiol Genomics 1999;1:83-91.
2. Boon K, Eberhart CG, Riggins GJ. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res 2005;65:703-7.
3. de Haas T, Oussoren E, Grajkowska W, et al. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol 2006;65:176-86.
4. Di C, Liao S, Adamson DC, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 2005;65:919-24.
5. -/- mutants due to a defective anterior neuroectoderm specification during gastrulation. Development 1995;121:3279-90.
6. Martinez S. The isthmic organizer and brain regionalization. Int J Dev Biol 2001;45:367-71.
7. Morsli H, Tuorto F, Choo D, Postiglione MP, Simeone A, Wu DK. Otx1 and Otx2 activities are required for the normal development of the mouse inner ear. Development 1999;126:2335-43.
8. Fossat N, Chatelain G, Brun G, Lamonerie T. Temporal and spatial delineation of mouse Otx2 functions by conditional self-knockout. EMBO Rep 2006;7:824-30.
9. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 2008;3:e3088.
10. Adamson DC, Shi Q, Wortham M, et al. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res 2010;70:181-91.
11. Roth RB, Hevezi P, Lee J, et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 2006;7:67-80.
12. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287-300.
13. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003;34:374-8.
14. Dennis G, Jr., Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:3.
15. El Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992;1:45-9.
16. Ren B, Robert F, Wyrick JJ, et al. Genome-wide location and function of DNA binding proteins. Science 2000;290:2306-9.
17. Langdon JA, Lamont JM, Scott DK, et al. Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Genes Chromosomes Cancer 2006;45:47-60.
18. Jacobsen PF, Jenkyn DJ, Papadimitriou JM. Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J Neuropathol Exp Neurol 1985;44:472-85.
19. Waha A, Waha A, Koch A, et al. Epigenetic silencing of the HIC-1 gene in human medulloblastomas. J Neuropathol Exp Neurol 2003;62:1192-201. (Pubitemid 37413829)
20. Raffel C, Thomas GA, Tishler DM, Lassoff S, Allen JC. Absence of p53 mutations in childhood central nervous system primitive neuroectodermal tumors. Neurosurgery 1993;33:301-5.
21. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006;6:472-6.
22. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 2008;27:2801-9.
23. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
24. Cichowski K, Hahn WC. Unexpected pieces to the senescence puzzle. Cell 2008;133:958-61.
25. Chandeck C, Mooi WJ. Oncogene-induced cellular senescence. Adv Anat Pathol 2010;17:42-8.
26. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009;9:81-94.
27. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008;133:1019-31.
28. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008;132:363-74.
29. Acampora D, Annino A, Puelles E, Alfano I, Tuorto F, Simeone A. OTX1 compensates for OTX2 requirement in regionalisation of anterior neuroectoderm. Gene Expr Patterns 2003;3:497-501.
30. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a). Cell 1997;88:593-602.
31. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years (vol 3, pg 459, 2003). Nat Rev Cancer 2003;3:708.
32. Zhuang D, Mannava S, Grachtchouk V, et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 2008;27:6623-34.
33. Debidda M, Williams DA, Zheng Y. Rac1 GTPase regulates cell genomic stability and senescence. J Biol Chem 2006;281:38519-28.
34. Zhu JY, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998;12:2997-3007.
35. Lazzerini DE, Attwooll C, Pasini D, Helin K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005;25:2660-72.
36. Mallette FA, Gaumont-Leclerc MF, Huot G, Ferbeyre G. Myc downregulation as a mechanism to activate the Rb pathway in STAT5A-induced senescence. J Biol Chem 2007;282:34938-44.
37. Ravi RK, McMahon M, Yangang Z, et al. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J Cell Biochem 1999;72:458-69.
38. Bihani T, Mason DX, Jackson TJ, Chen SC, Boettner B, Lin AW. Differential oncogenic Ras signaling and senescence in tumor cells. Cell Cycle 2004;3:1201-7.
39. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
40. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118.
41. Di Micco R, Fumagalli M. Breaking news: high-speed race ends in arrest-how oncogenes induce senescence. Trends Cell Biol 2007;17:529-36.
42. Grandori C, Wu KJ, Fernandez P, et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 2003;17:1569-74.
43. Adesina AM, Nalbantoglu J, Cavenee WK. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 1994;54:5649-51.
44. Badiali M, Iolascon A, Loda M, et al. p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing. Diagn Mol Pathol 1993;2:23-8.
45. Cogen PH, Daneshvar L, Metzger AK, Duyk G, Edwards MS, Sheffield VC. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis. Am J Hum Genet 1992;50:584-9.
46. Tong CY, Hui AB, Yin XL, et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg 2004;100:187-93.
47. Castellino RC, De Bortoli M, Lu X, et al. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 2008;86:245-56.
48. Ehrbrecht A, Muller U, Wolter M, et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 2006;208:554-63.
49. Mendrzyk F, Radlwimmer B, Joos S, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005;23:8853-62.
50. Rollbrocker B, Waha A, Louis DN, Wiestler OD, von Deimling A. Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol 1996;92:70-4.
51. Lo KC, Rossi MR, Burkhardt T, Pomeroy SL, Cowell JK. Overlay analysis of the oligonucleotide array gene expression profiles and copy number abnormalities as determined by array comparative genomic hybridization in medulloblastomas. Genes Chromosomes Cancer 2007;46:53-66. (Pubitemid 44772872)
52. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006;24:1924-31.